What question did this study set out to answer?

The study aims to identify and describe sociodemographic disparities in treatment patterns and outcomes for women with HR+/HER2– metastatic breast cancer.

February 2, 2026Cancer Epidemiology Biomarkers & PreventionOpen Access

Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women With HR+/HER2– Metastatic Breast Cancer

View Full Paper

Ask AI

Bookmark

Authors

GVGregory A. VidalWest Cancer Center JKJulie KatzGilead Sciences (United States)NSNatalia Sadetsky

Discussion

Member takes

Implication

Retrospective analysis reveals treatment disparities in HR+/HER2– metastatic breast cancer among U.S. women, indicating access gaps.

Key Points

The study aims to identify and describe sociodemographic disparities in treatment patterns and outcomes for women with HR+/HER2– metastatic breast cancer.
Conducted a retrospective, observational cohort study using de-identified health records from Flatiron Health.
Included women aged 18 years and older in the U.S. who received first-line treatment for HR+/HER2– metastatic breast cancer from 2015 to 2023.
Assessed real-world overall survival (rwOS) and time to next treatment or death (rwTTNTD) using Kaplan-Meier methods.
The analysis included 6,974 women, primarily non-Hispanic White and treated in community settings.
Non-Hispanic White women were more likely to receive endocrine therapy and CDK4/6 inhibitors compared to non-Hispanic Black and Hispanic women.
Non-Hispanic White women had significantly longer rwOS than non-Hispanic Black women but shorter than that of Hispanic/Latino women.

Cite This Study

Vidal et al. (2026) studied this question.

synapsesocial.com/papers/6980fdc7c1c9540dea80f6dc https://doi.org/10.1158/1055-9965.epi-25-1459

View Full Paper

Ask AI

Bookmark

Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women With HR+/HER2– Metastatic Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women With HR+/HER2– Metastatic Breast Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider